Articles tagged with Alzheimer Disease
Researchers found a potential new risk factor for dementia and Alzheimer's disease in women, linking the hormone adiponectin to an increased risk. Elevated levels of adiponectin were associated with an increased risk of all-cause dementia and AD in women, contrary to its expected anti-inflammatory properties.
Research suggests that cerebrospinal fluid biomarkers can identify individuals at high risk for Alzheimer's disease up to 5-10 years before symptoms appear. Studies found reduced Aβ42 and elevated T-tau and P-tau levels in patients with mild cognitive impairment who later developed Alzheimer's.
A study found that individuals with smaller brain cortex regions are more likely to develop early symptoms of Alzheimer's disease. The research identified 21% of those at high risk for cognitive decline, compared to 7% of those at average risk.
A study by VTT Technical Research Centre of Finland and University of Eastern Finland reveals a biochemical signature indicative of hypoxia and up-regulated pentose phosphate pathway that can predict progression to Alzheimer's disease. This indicator can be analyzed from serum samples months or years before first symptoms occur.
Researchers developed a method to detect cognitive decline in Parkinson's patients using MRI brain scans, revealing higher Alzheimer's patterns of atrophy predict worsening cognition. The study found an overlap between the two neurodegenerative diseases, raising hopes for early diagnosis and treatment.
Scientists at Rensselaer Polytechnic Institute have designed a new method to create antibodies that neutralize the harmful protein particles leading to Alzheimer's disease. The process targets specific portions of the toxic protein, allowing for better understanding and potential treatment of similar diseases like Parkinson's.
Researchers have found a natural dye from lichens that reduces the abundance of small toxic protein aggregates in Alzheimer's disease, promoting their conversion into large non-toxic plaques. Further studies are needed to determine its effectiveness for therapy development and potential benefits for patients.
A study found that consuming baked or broiled fish on a weekly basis preserves gray matter volume in areas at risk for Alzheimer's disease. This reduction in risk is associated with improved cognitive function, particularly working memory.
Researchers have discovered a new marker that can accurately diagnose Alzheimer's disease versus frontotemporal lobar degeneration (FTLD), two types of dementia sharing similar symptoms. The PIB PET scan outperformed the FDG scan in differentiating between the two conditions, with higher sensitivity and accuracy.
Research reveals that caregivers' daily lives are disrupted by their loved one's behaviors, leading to elevated stress levels and physical health risks. The study also found that caregiving can tax the caregiver's HPA system, contributing to cardiovascular and metabolic problems.
A study published in The Journal of Cell Biology found that poor recycling of the BACE1 enzyme could promote Alzheimer's disease. Reduced levels of the retromer component VPS35 led to enhanced BACE1 activity and increased Abeta protein formation, contributing to disease progression.
A recent study found that individuals with mild cognitive impairment and no memory problems who had the Alzheimer's biomarkers were more likely to have a lower BMI than those without the biomarkers. This association suggests a systemic metabolic response to the disease, possibly related to damage in the hypothalamus.
Researchers developed a new MRI technique called Arterial spin labeling (ASL) to measure changes in brain function, potentially replacing the current standard PET scan. The study found that ASL-MRI is comparable to FDG-PET in detecting Alzheimer's disease and has the advantage of being non-invasive and widely available.
University of Michigan researchers will provide genetic testing and risk estimates for individuals with mild cognitive impairment. The study aims to evaluate the impact of health education and genetic testing on psychological adjustment and behavior changes.
Dr. David Llewellyn has been awarded a two-year grant to investigate the link between low vitamin D levels and increased risk of dementia. His research aims to identify vitamin D as a potential biomarker and therapeutic target for preventing and treating the disease.
Researchers at UGA have developed the world's first transgenic mouse model with Hirano bodies, which may play a protective role in the progression of neurodegenerative diseases such as Alzheimer's. The new model will allow scientists to study the impact of Hirano bodies on cell survival and disease progression.
Scientists have discovered that Alzheimer's protein tangles involve at least three different proteins, including neurofilaments and vimentin, in addition to the previously identified tau protein. This discovery could lead to a better understanding of the disease's progression and potential new drug targets.
Researchers use yeast, worms, and rats to study the effects of amyloid beta peptide misfolding on cellular pathways. The study reveals a crucial link between protein misfolding and Alzheimer's disease, highlighting potential new avenues for understanding and combating the disorder.
Researchers have identified a dozen genetic modifiers of amyloid beta toxicity in yeast, including several linked to Alzheimer's disease risk by genome-wide association studies. The yeast model also showed that these genes can suppress Aβ-induced neuronal loss in worms and cultured rat neurons.
A recent study found that nearly 37% of Alzheimer's patients taking cholinesterase inhibitors also received anticholinergic drugs, which can have negative effects on cognition and function. However, the study revealed no association between dual use and increased risk of death or nursing home entry.
Researchers found that cataract surgery improved cognitive ability, mood, and sleep patterns in mild Alzheimer's disease patients. The study suggests that vision correction may boost quality of life for these patients and their families.
Researchers used a combination of MRI, cerebrospinal fluid, and neuropsychological testing to improve predictive accuracy for near-term dementia conversion. The test results were found to be almost perfect in predicting those who would not develop Alzheimer's disease in three years.
Researchers at UT Austin develop automated system to test millions of drugs on C. elegans worm, which develops Alzheimer's disease similar to humans. The goal is to speed up drug discovery and development for neurodegenerative diseases.
Researchers discovered that antiviral agents can decrease the accumulation of AD proteins β-amyloid and P-tau in HSV1-infected cells. The study suggests that these agents might be effective in slowing Alzheimer's progression, targeting a cause rather than symptoms.
Researchers at St. Michael's Hospital found that bilingual individuals have twice as much brain damage as unilingual people before they exhibit symptoms of Alzheimer's disease. This delay may be due to the constant activation and compensation of brain networks in bilingual individuals.
Researchers found that altering a specific site on the NMDA receptor subunits reduced activity and calcium overload in neurons, potentially leading to new therapies for Alzheimer's and stroke. The discovery offers a promising opportunity for rationally designing drugs with more precise effects.
The Indiana Network for Patient Care will enhance its infrastructure with an $8.4 million grant, supporting a comparative effectiveness study on three Alzheimer's drugs. The study aims to provide critical guidance to clinicians nationwide, helping them determine the best treatment for patients.
Research by biologists at the University of York has revealed that under stressful conditions, synapses can grow excessively, potentially contributing to dysfunction. This finding has strong implications for neuronal function as brains age and adds significantly to our understanding of neurodegenerative diseases.
A Mayo Clinic study recommends adding categories to more effectively identify and treat people with preclinical Alzheimer's disease, a long latent stage of the disease. The researchers suggest two additional sub-groups: Stage 0 (normal biomarkers and no cognitive impairment) and SNAP patients (with suspected non-AD pathophysiology).
A small study found that gantenerumab, a medication for Alzheimer's disease, reduced brain amyloid levels. The treatment led to dose-dependent amyloid reduction in patients with mild-to-moderate AD.
Researchers found that 95% of people aged 65 have brain small vessel disease, while a quarter of healthy seniors have silent strokes. Regular exercise can delay onset of late life dementia, says Dr. Sandra Black.
A study by UTHealth suggests that Alzheimer's disease may arise from an infectious process similar to other neurological diseases. Researchers injected brain tissue from a confirmed Alzheimer's patient into mice, which developed plaques and brain alterations typical of the disease.
A team of scientists has discovered a link between pregnancy protein and Alzheimer's disease, finding elevated levels in women destined for the condition years before symptoms appear. They found that the protein, pregnancy zone protein, is being produced in senile plaques, a hallmark of AD.
New research suggests that prenatal exercise improves brain plasticity, decreases toxic protein deposits and inflammation in mice, which wards off Alzheimer's disease. Exercise during pregnancy may have a lifetime benefit for the health of newborns.
A daily pattern of rising and falling amyloid beta levels in spinal fluid echoes the sleep cycle, with younger individuals exhibiting stronger highs and lows. As people age, this pattern flattens, potentially providing an opportunity for the body to clear away the Alzheimer's marker.
Researchers have identified micro-RNA 34c as a key regulator of learning and Alzheimer's disease. Elevated levels of miRNA 34c are associated with memory impairment, while lowering its levels can restore learning ability in mouse models of Alzheimer's disease.
Researchers at Douglas Mental Health University Institute are launching the world's first prevention study on Alzheimer's disease. They will recruit 250 healthy adults aged 60 or over with a family history of the condition and observe their biomarkers for ten years to find preventative agents.
A new report from the University of Pennsylvania School of Medicine calls for policies to prepare individuals and society for earlier diagnosis of Alzheimer's. Safeguards are needed to protect those at high risk or with a pre-clinical diagnosis, including laws and policies to prevent stigma and discrimination.
A study led by the University of South Florida found that decreasing expression of protein FKBP51 in old mice made them resistant to depressive-like behavior, improving their hormonal response to stress. The lack of this protein did not adversely affect their memory or basic motor functions.
A recent study has found a significant link between high cholesterol levels and the presence of brain plaques associated with Alzheimer's disease. Researchers tested 2,587 people aged 40-79 and found that those with high cholesterol had significantly more brain plaques than those with normal or lower cholesterol levels.
A randomized controlled trial found that intranasal insulin therapy improved delayed story recall and preserved general cognition in adults with mild cognitive impairment or Alzheimer's disease. The treatment also stabilized cerebral glucose metabolism and functional abilities in older adults.
A new study identifies a novel link between neuroinflammation and Alzheimer's disease pathology, revealing that an inflammatory mediator enhances A² protein plaque formation. The research also highlights the potential therapeutic target of NOS2 inhibition for treating AD.
Researchers identify key protein ABCCC1 in clearing Alzheimer's beta-amyloid from the brain. A mutation in PSMB8 gene causes Japanese autoinflammatory syndrome with lipodystrophy. Signaling via TACI is crucial for long-lived antibody-secreting cells in a mouse model of flu infection.
Researchers have identified a way to reduce beta-amyloid in mouse brains with AD, suggesting that activating ABCC1 transport protein could impede amyloid plaque formation. The approach uses thiethylperazine to activate ABC transporters and has potential for treating Alzheimer's disease.
Researchers found that Alzheimer's brains consistently show lower levels of ubiquilin-1, a chaperone protein that helps regulate amyloid precursor protein (APP). Lower ubiquilin-1 levels disrupt APP folding and lead to the formation of toxic aggregates.
A team of UBC researchers found nearly double the density of capillaries in brain tissue from Alzheimer's mouse models and human samples compared to healthy individuals. This 'neo-angiogenesis' may lead to a breakdown of the blood-brain barrier, allowing harmful substances to enter the brain.
Researchers at Yale University have developed a practical method to synthesize huperzine A, a natural enzyme inhibitor that has been used to treat Alzheimer's disease in China. The compound shows promise in combating the effects of chemical warfare agents and may offer improved therapeutic benefits compared to existing treatments.
A study using advanced brain imaging techniques found that 33% of participants had high levels of amyloid-beta deposits, indicating an increased risk of Alzheimer's disease. The study also discovered a link between these deposits and changes in brain metabolites, which may help identify people at risk for the condition.
A researcher has found that individuals with Down syndrome have substantially altered key eye reflexes, leading to poor balance and motor coordination. The study's findings could lead to new tools for assessing the effectiveness of treatments aimed at improving quality of life.
Blocking a transport pathway through brain cells offers new prospects for preventing Alzheimer's disease development. Researchers discovered that the amyloid beta precursor protein and beta secretase enzyme follow different paths, leading to the formation of amyloid plaques.
The University of Kentucky Sanders-Brown Center on Aging is receiving over $7 million from the National Institute on Aging to continue its research and clinical initiatives focused on treating Alzheimer's disease. The funding will support ongoing programs, including telemedicine services, brain donation, and outreach efforts.
Researchers at Lund University have discovered a new function for vitamin C, finding that it can dissolve toxic protein aggregates in the brain that build up in people with Alzheimer's disease. The treatment has potential to delay and alleviate the progression of the disease by addressing its symptoms.
A study found positive associations between fish oil supplements and cognitive functioning, as well as differences in brain structure between users and non-users. Fish oil use was associated with increased average brain volumes and smaller brain ventricular volumes compared to non-users.
A modified form of the enzyme Cdk5 is elevated in Alzheimer's disease patients, triggering damage to nerve cell connections. This discovery suggests that SNO-Cdk5 could be targeted for the development of new Alzheimer's disease therapies.
Researchers discovered striking similarities in gene expression patterns between healthy aging and neurodegenerative diseases, including Alzheimer's. Aging-related changes were found in individuals as young as 50, contradicting previous expectations.
A new study suggests that Alzheimer's disease symptoms are less noticeable in people over 80 compared to those between 60-75. Brain scans revealed that executive function, memory, and attention were less abnormal in older adults.
A new diagnostic test is being developed to pick up the presence of Alzheimer's disease and other dementias much sooner than possible currently, allowing for more effective treatment. The research could mean patients will receive timely treatment that slows down devastating symptoms.
Columbia University researchers have successfully converted human skin cells directly into functional forebrain neurons, providing a promising alternative to traditional stem cell therapies. The induced neurons exhibit characteristics similar to those of healthy neurons and can transmit signals, indicating their potential for replaceme...
Researchers develop a method to convert human skin cells into neurons, offering a potential shortcut for generating replacement therapies. The new approach has already yielded insights into Alzheimer's disease and could be used for testing new drug candidates.
At the University of Houston, 54 undergraduates are devoting their summers to serious research under faculty mentorship. They aim to find solutions for maladies including Alzheimer's, high blood pressure, cholesterol, diabetes, alcoholism and anxiety. Through projects like studying oxidative stress and its relation to disorders, as wel...